Nadya Lisovoder, chief medical officer at MGC Pharmaceuticals, discusses with Proactive the results from the phase II trial of dementia treatment Cognicann.
The results are revolutionary, she says, because it was the first trial that was managed in the academic facility to prove the safety and efficacy of dementia patients receiving a cannabis-based product.